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Introduction: Systemic sclerosis, a rare disease in childhood, is characterized by skin 
fibrosis, internal organ involvement, and vasculopathy. Juvenile systemic sclerosis 
(JSSc) represents less than 10% of all scleroderma patients. 
Objectives: To describe the clinical characteristics and disease progression of children 
with JSSc followed in Portuguese pediatric rheumatology centers. 
Methods: Clinical and laboratory features as well as medication and outcome of 
children who met classification criteria for JSSc were reviewed. 
Results: Fifteen patients were identified and included in the analysis, 3 of them were 
overlap syndromes. Eleven girls (73%), 13 (87%) Caucasians, with a mean age at 
diagnosis of 11.1±3.0 (3–15) years and a mean disease duration of 7.2±4.2 years (8 
months-17 years). In 14 (93%) cases, the first symptom attributable to JSSc was 
Raynaud’s phenomenon, followed by arthritis and/or puffy hands (9 patients, 60%). At 
disease diagnosis 12 (80%) patients presented periungual capillaropathy and in 8 
patients, pulmonary involvement was documented, despite the absence of respiratory 
complaints. Cumulative disease manifestations as well as complications developed 
during follow-up are shown in table 1. 
All but one child were ANA positive (93%), 7 tested positive for anti-Scl70, 2 positive 
for anti-RNP and 1 for anti-fibrillarin antibodies. There were no cases of anti-
centromere antibodies. 
Immunosuppressants (93%), proton pump inhibitors (80%), calcium channel blockers 
(53%) and corticosteroids (60%) were the most common therapeutic options. Five and 
four children were treated with prostacyclin analogues and ET-1 receptor antagonist, 
respectively. One child needed autologous bone marrow transplant due to severe 
refractory disease.  
An improvement of skin thickening and stabilization of pulmonary involvement was 
documented in most cases. No deaths were registered in this cohort. Table 1. 
 
  
Conclusion: Conclusions: Diffuse cutaneous disease was the subtype of JSSc more 
prevalent identified in pediatric rheumatology centers. Raynaud’s phenomenon as well 
as capillaroscopic abnormalities are almost universal at disease presentation. Internal 
organ involvement is common and occurs early during disease course, although 
clinically silent in several cases.  
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Diffuse 
cutaneous 
disease
Digital ulcers Calcinosis 
Musculoskeletal 
involvement
Interstitial lung 
disease
Cardiac disease
Gastrointestinal 
disease
Renal disease
15 (100%) 11 (73%)  3 (20%) 13 (87%)  8 (53%) 2 (13%) 7 (47%) 1 (7%)
Table 1: Cumulative manifestations and complications observed during the follow-up
